Literature DB >> 15774440

Mirtazapine increases cortical excitability in healthy controls and epilepsy patients with major depression.

A Münchau1, J M Langosch, W Gerschlager, J C Rothwell, M Orth, M R Trimble.   

Abstract

BACKGROUND: Epilepsy is often complicated by depression requiring antidepressant treatment. Such treatment might be proconvulsive.
OBJECTIVE: To examine the effects of the noradrenergic and specific serotonergic antidepressant mirtazapine on motor cortex excitability in epilepsy patients with depression and in healthy controls, using transcranial magnetic stimulation (TMS).
METHODS: Seven clinically depressed epilepsy patients treated with anticonvulsant drugs and six healthy volunteers were studied. Before intake of mirtazapine and 24 hours afterwards (and also three weeks afterwards in the patients), the active and resting motor threshold (AMT, RMT), the size of the motor evoked potential (MEP), the cortical silent period (SP), and intracortical inhibition/facilitation and intracortical facilitatory I wave interactions were determined using single and paired pulse TMS.
RESULTS: At baseline, AMT and RMT were higher (p = 0.049 and p = 0.04, respectively) and the ratio SP duration/MEP area greater in patients (p = 0.041). In patients but not in healthy subjects AMT was lower 24 hours after intake of mirtazapine (p = 0.028). Mirtazapine had no significant effect on the MEP size, duration of the SP, or the ratio of SP duration to MEP size in patients. The duration of the SP was longer (p = 0.037) but the ratio of SP duration to MEP size remained similar in healthy subjects after mirtazapine. There were no significant differences in paired pulse measures between the two groups either at baseline or after mirtazapine.
CONCLUSIONS: Mirtazapine increased neuronal excitability of pyramidal tract axons in an activated state in both healthy controls and epilepsy patients with major depression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774440      PMCID: PMC1739580          DOI: 10.1136/jnnp.2004.037010

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  42 in total

1.  Demonstration of facilitatory I wave interaction in the human motor cortex by paired transcranial magnetic stimulation.

Authors:  U Ziemann; F Tergau; E M Wassermann; S Wischer; J Hildebrandt; W Paulus
Journal:  J Physiol       Date:  1998-08-15       Impact factor: 5.182

2.  Mirtazapine pharmacokinetics with two dosage regimens and two pharmaceutical formulations.

Authors:  C J Timmer; J E Paanakker; M Vrijmoed-de Vries
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

Review 3.  The safety of fluoxetine--an update.

Authors:  G L Cooper
Journal:  Br J Psychiatry Suppl       Date:  1988-09

4.  Effects of phenytoin on cortical excitability in humans.

Authors:  R Chen; A Samii; M Caños; E M Wassermann; M Hallett
Journal:  Neurology       Date:  1997-09       Impact factor: 9.910

5.  Transcranial magnetic stimulation in partial epilepsy: drug-induced changes of motor excitability.

Authors:  R Michelucci; D Passarelli; P Riguzzi; A M Buzzi; E Gardella; C A Tassinari
Journal:  Acta Neurol Scand       Date:  1996-07       Impact factor: 3.209

6.  Effects of left frontal transcranial magnetic stimulation on depressed mood, cognition, and corticomotor threshold.

Authors:  W J Triggs; K J McCoy; R Greer; F Rossi; D Bowers; S Kortenkamp; S E Nadeau; K M Heilman; W K Goodman
Journal:  Biol Psychiatry       Date:  1999-06-01       Impact factor: 13.382

7.  Effects of the serotonin1B/1D receptor agonist zolmitriptan on motor cortical excitability in humans.

Authors:  K J Werhahn; S Förderreuther; A Straube
Journal:  Neurology       Date:  1998-09       Impact factor: 9.910

Review 8.  Regulation of membrane excitability in the central nervous system by serotonin receptor subtypes.

Authors:  R Andrade
Journal:  Ann N Y Acad Sci       Date:  1998-12-15       Impact factor: 5.691

9.  Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine.

Authors:  Christian Plewnia; Julia Hoppe; Christoph Hiemke; Mathias Bartels; Leonardo G Cohen; Christian Gerloff
Journal:  Neurosci Lett       Date:  2002-09-27       Impact factor: 3.046

10.  Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study.

Authors:  U Ziemann; S Lönnecker; B J Steinhoff; W Paulus
Journal:  Ann Neurol       Date:  1996-09       Impact factor: 10.422

View more
  5 in total

1.  Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation.

Authors:  Albino J Oliveira-Maia; Daniel Press; Alvaro Pascual-Leone
Journal:  Brain Stimul       Date:  2017-03-31       Impact factor: 8.955

Review 2.  Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Authors:  Katherine F Croom; Caroline M Perry; Greg L Plosker
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

3.  Transcranial magnetic stimulation neurophysiology of patients with major depressive disorder: a systematic review and meta-analysis.

Authors:  Megumi Kinjo; Masataka Wada; Shinichiro Nakajima; Sakiko Tsugawa; Tomomi Nakahara; Daniel M Blumberger; Masaru Mimura; Yoshihiro Noda
Journal:  Psychol Med       Date:  2020-12-03       Impact factor: 7.723

4.  Pharmacological treatment with mirtazapine rescues cortical atrophy and respiratory deficits in MeCP2 null mice.

Authors:  Tamara Bittolo; Carlo Antonio Raminelli; Chiara Deiana; Gabriele Baj; Valentina Vaghi; Sara Ferrazzo; Annalisa Bernareggi; Enrico Tongiorgi
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

5.  Probing the Brain-Body Connection Using Transcranial Magnetic Stimulation (TMS): Validating a Promising Tool to Provide Biomarkers of Neuroplasticity and Central Nervous System Function.

Authors:  Arthur R Chaves; Nicholas J Snow; Lynsey R Alcock; Michelle Ploughman
Journal:  Brain Sci       Date:  2021-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.